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Idiopathic pulmonary fibrosis (IPF) 
is a progressive, irreversible lung 
disease, characterized by chronic 
inflammation and fibroproliferation 
of the parenchymal cells of the lung 
that lead to chronic respiratory 
failure and ultimately death 
(Kotsianidis et al., 2009). IPF is 
more prevalent in men than in 
women and risk for disease 
increases after age 60. IPF is the 
most common form of idiopathic 
interstitial pneumonia and it affects 
over 100,000 persons in the United 
States alone (Ding et al., 2011). Most 
of IPF cases are considered to be 
unpredictable and sporadic in 
nature, however approximately 15-
20% of cases have a family history 
of IPF and linked to autosomal 
dominance disorder (Tsang, Wyatt, 
Ting, & Beattie, 2012). IPF is a 
debilitating disease with minimal 
treatment options and current 
research is being done to determine 
treatments that will optimize 
patient’s lung capacity and improve 
quality of life. Though efforts are 
being made to decrease morbidity 
and mortality of this disease IPF 
remains to have a poor prognosis 
because it responds very little to 
medications and other treatments. 
Median survival after diagnosis is 
two to three years (Putman, Rosas, 
& Hunninghake, 2014).  
Pathophysiology 
Extensive research on the development 
and underlying etiology of IPF has been 
studied over the years. Though the 
pathophysiology of IPF is complex and 
not entirely understood, Hauber & 
Blaukovitsch (2010) simply stated that 
IPF is an autoimmune disease that 
results in a fibrotic lung from underlying 
epithelial injury of unknown cause and 
abnormal healing of the alveolar-capillary 
barrier basement membrane due to 
dysregulated tissue repair of epithelial 
and endothelial cells (p. 159).  
Taille et al. (2010) presented data that 
strongly suggests that IPF is an 
autoimmune disease. First piece of data 
that strongly suggests that IPF is 
autoimmune is the presence of B-cell 
aggregates on an observed IPF lung; 
organized with activated T lymphocytes 
and mature dendritic cells suggesting 
significant antigen activity in the lung 
parenchyma. Second, circulating CD4 T 
cells from the patient with IPF exhibits 
immune activation. CD4 T cells help 
produce cytokines and also fibrogenic 
mediators, such as IL-10, transforming 
growth factor β-1, or tumor necrosis 
factor-α. Third, CD 4 T cells purified from 
lymph nodes from patients with IPF 
proliferate when cultured with 
autologous lung tissue protein extracts. 
The responsible antigen(s) is still 
unidentified but several studies point to 
the alveolar epithelial cell as a possible 
target of autoimmunity in IPF (p. 759).  
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Signs & Symptoms 
Subjective: 
• worsening dyspnea  
• dry cough 
• chest pain 
• fatigue 
• low-grade fever 
• weight loss 
Objective:  
• bilateral inspiratory crackles 
• nailbed clubbing  
• increased pulmonic second heart 
sound 
• right ventricular lift 
• tricuspid regurgitation 
• Cyanosis (late clinical 
manifestation) (Ryu et al., 2014). 
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Diagnosis 
Recently discovered biomarkers that can 
help assist in the diagnostic and prognostic  
identification of IPF are available through 
peripheral blood smears. These biomarkers 
include: 
• matrix metalloproteinases (MMP-1 & 
MMP-7)  
• Krebs von den Lungen 6 (KL-6) which 
is a glycoprotein that is expressed 
mainly on type II pneumocytes 
• surfactant protein A 
• CD28 cells 
• circulating myofibroblasts  
• presence of oxidative stress  
• (Torrens & Iwata, 2012).  
Some of these biomarkers can be useful in 
staging IPF because the more biomarkers 
detected indicates the amount of alveolar 
epithelial cell injury.  
Other laboratory tests:  
• Increased WBC  
• C-reactive protein  
• lactate dehydrogenase.  
• ABG- hypoxemia and hypercapnea & 
anticipate any need for mechanical 
ventilation (Bhatti, Girdhar, Usman, 
Cury, & Bajwa, 2013).  
Idiopathic pulmonary fibrosis is a diagnosis 
of exclusion. In addition to the blood serum 
tests, a CT scan, bronchoalveolar lavage, and 
lung biopsy should be obtained. A hallmark 
sign of IPF on CT scan reveals extensive 
“honeycombing” and results of lung biopsy 
shows typical usual interstitial pneumonia 
(UIP) pattern, diffuse alveolar damage with 
or without hyaline membranes, numerous 
fibroblastic foci, and hemorrhage with 
capillaritis (Bhatti, Girdhar, Usman, Cury, & 
Bajwa, 2013).  
Patients with IPF often develop pulmonary 
hypertension (PH) and right ventricular 
hypertrophy due to pulmonary vascular 
remodeling from hypoxic vasoconstriction 
thus echocardiogram should be used to help 
determine the extent of IPF. Approximately 
85% of patients with end-stage IPF have PH 
(Ryu et al., 2014). Another common 
comorbidity of IPH is gastroesophageal 
reflux disease (GERD). Increased levels of 
pepsin are seen in the bronchoalveolar 
lavage fluid of IPF patients and suggest 
gastric aspiration. Others include lung 
cancer that can be difficult to diagnose due 
to fibrotic changes in the lungs but typically 
appear as irregular nodules, also venous 
thromboembolic disease due to 
immobilization (Ryu et al., 2014).  
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Nursing Implications 
Idiopathic pulmonary fibrosis has a poor prognosis with median survival of 2-
3 years thus as the nurse it is important to provide support, coping strategies, 
education regarding IPF, adjusting to a new lifestyle and offering pulmonary 
rehabilitation tailored to their needs and progression of disease (Duck, 2014). 
The nurse is also required to optimize patient’s quality of life by supportive 
care and symptom management such as oxygen therapy for worsening 
hypoxia, treatment for cough, frequent pulmonary function testing to monitor 
progression of disease, consultation to palliative care, assessment and 
management of other comorbidities, and smoking cessation advice. 
Pharmacological interventions include steroid, immunosuppressant, and n-
acetylcysteine (Duck, 2014).  
Conclusion 
Although idiopathic pulmonary 
fibrosis remains a debilitating and 
untreatable disease our 
understanding of the disease and its 
progression continues to advance as 
more research is being done to 
reveal its physiological 
characteristics, however effective 
therapy has remained indefinable. 
Palliative care education should be 
provided to the patient and family, as 
supportive care is the optimal 
therapy for this patient.   
Gardet, A., Zheng, T., Viney, J. (2013). Genetic architecture of human fibrotic diseases: 
disease risk and disease progression [Figure 1]. Retrieved from 
http://journal.frontiersin.org/Journal/10.3389/fphar.2013.00159/full  
Bhatti, H., Girdhar, A., Usman, F., Cury, J., & 
Bajwa, A. (2013). Approach to acute 
exacerbation of idiopathic pulmonary 
fibrosis. Annals Of Thoracic Medicine, 8(2), 
71-78. doi:10.4103/1817-1737.109815 
Ding, Q., Luckhardt, T., Hecker, L., Zhou, Y., 
Liu, G., Antony, V. B., deAndrade, J., & 
Thannickal, V. J. (2011). New Insights into the 
Pathogenesis and Treatment of Idiopathic 
Pulmonary Fibrosis. Drugs, 71(8), 981-1001. 
doi:10.2165/11591490-000000000-00000 
Duck, A. (2014). Management of idiopathic 
pulmonary fibrosis. Nursing Times, 110, 16-
7. Retrieved from http://ezproxy.otterbein. 
edu/login?url=http://search.proquest.com/d
ocview/1521727184?accountid=28350  
Hauber, H., & Blaukovitsch, M. (2010). 
Current and future treatment options in 
idiopathic pulmonary fibrosis. Inflammation 
& Allergy Drug Targets, 9(3), 158-172. 
Kotsianidis, I., Nakou, E., Bouchliou, I., 
Tzouvelekis, A., Spanoudakis, E., 
Steiropoulos, P., & …Bouros, D. (2009). Global 
impairment of 
CD4+CD25+FOXP3+regulatory T cells in 
idiopathic pulmonary fibrosis. American 
Journal of Respiratory & Critical Care 
Medicine, 179(12), 1121-1130, 
doi:10.1164/rccm.200812-1936OC 
Putman, R., Rosas, I., & Hunninghake, G. 
(2014). Genetics and early detection in 
idiopathic pulmonary fibrosis. American 
Journal Of Respiratory & Critical Care 
Medicine, 189(7), 770-778. 
doi:10.1164/rccm.201312-2219PP 
Ryu, J., Moua, T., Daniels, C., Hartman, T., Yi, 
E., Utz, J., & Limper, A. (2014). Idiopathic 
pulmonary fibrosis: evolving concepts. Mayo 
Clinic Proceedings, 89(8), 1130-1142. 
doi:10.1016/j.mayocp.2014.03.016  
Torrens, D., & Iwata, R. (2012). Serum 
biomarkers for lung disease: Biomarkers can 
play an important role in the management of 
idiopathic pulmonary fibrosis and other 
interstitial lung diseases. MLO: Medical 
Laboratory Observer, 44(7), 38-42 
Taille, C., Grootenboer-Mignot, S., Boursier, C., 
Michel, L., Debray, M.P., Fagart, J., Barrientos, 
L., … Crestani, B. (2010). Identification of 
periplakin as a new target for autoreactivity 
in idiopathic pulmonary fibrosis. American 
Journal Of Respiratory And Critical Care 
Medicine, 183, 759-766. 
doi:10.1164/rccm.201001-0076OC 
Tsang, A., Wyatt, H., Ting, N., & Beattie, T. 
(2012). hTERT mutations associated with 
idiopathic pulmonary fibrosis affect 
telomerase activity, telomere length, and cell 
growth by distinct mechanisms. Aging Cell, 
11(3), 482-490. doi:10.1111/j.1474-
9726.2012.00810.x  
Honeycombing 
Fibrous 
Connective 
Tissue 
